Your browser doesn't support javascript.
loading
Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
Bernardini, Nicoletta; Skroza, Nevena; Marchesiello, Anna; Mambrin, Alessandra; Proietti, Ilaria; Tolino, Ersilia; Maddalena, Patrizia; Marraffa, Federica; Rossi, Giovanni; Volpe, Salvatore; Potenza, Concetta.
Affiliation
  • Bernardini N; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Skroza N; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Marchesiello A; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Mambrin A; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Proietti I; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Tolino E; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Maddalena P; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Marraffa F; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Rossi G; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Volpe S; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Potenza C; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
Dermatol Ther ; 35(10): e15306, 2022 10.
Article in En | MEDLINE | ID: mdl-35100460
Psoriasis is a multifactorial, chronic, auto- inflammatory disease, with a worldwide prevalence of around 2%, subtended by robust genetic predisposition and autoimmune pathogenic traits. The disease, mainly involving the skin and joints, is featured by erythemato-squamous lesions, with a chronic relapsing course and relevant systemic comorbidities. Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Although it is considered as relatively safe molecule with few contraindications, experience with Apremilast in the real-world setting for cancer patients with moderate-to-severe plaque psoriasis is lacking. Hence, we report the real-life experience in patients with psoriasis and a history of cancer who underwent treatment with Apremilast for 104 weeks.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Arthritis, Psoriatic / Neoplasms Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Dermatol Ther Journal subject: DERMATOLOGIA Year: 2022 Document type: Article Affiliation country: Italy Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Arthritis, Psoriatic / Neoplasms Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Dermatol Ther Journal subject: DERMATOLOGIA Year: 2022 Document type: Article Affiliation country: Italy Country of publication: United States